Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Sheryl L. Chow"'
Autor:
Jeffrey Wang, Sheryl L Chow, Moses S S Chow, Amy Paik, Stan G Louie, Fanglong Dong, Airani Sathananthan, Stephanie White
Publikováno v:
The Journal of Sexual Medicine.
Background Oral vardenafil (VDF) tablet is an effective treatment for erectile dysfunction (ED), but intranasal administration with a suitable formulation can lead to a faster onset of action and offer more convenient planning for ED treatment. Aim T
Autor:
Sheryl L, Chow, Biykem, Bozkurt, William L, Baker, Barry E, Bleske, Khadijah, Breathett, Gregg C, Fonarow, Barry, Greenberg, Prateeti, Khazanie, Jacinthe, Leclerc, Alanna A, Morris, Nosheen, Reza, Clyde W, Yancy
Publikováno v:
Circulation.
Complementary and alternative medicines (CAM) are commonly used across the world by diverse populations and ethnicities but remain largely unregulated. Although many CAM agents are purported to be efficacious and safe by the public, clinical evidence
Autor:
Sheryl L. Chow, Wilson M. Compton, Elizabeth M. Oliva, Ivor J. Benjamin, Comilla Sasson, Eduardo Sanchez, Robert M. Califf, Chester Robson
Publikováno v:
Circulation. 144
The misuse of opioids continues to be epidemic, resulting in dependency and a recent upsurge in drug overdoses that have contributed to a significant decrease in life expectancy in the United States. Moreover, recent data suggest that commonly used o
Autor:
Robert S. McKelvie, Inder S. Anand, Sheryl L. Chow, Michel Komajda, Thomas S. Rector, Parul U. Gandhi, Hanna K. Gaggin, Michael R. Zile, John J.V. McMurray, Henry Krum, Peter E. Carson, James L. Januzzi
Publikováno v:
Journal of Cardiac Failure. 23:20-28
Background: The prognostic merit of insulin-like growth factor-binding protein 7 (IGFBP7) is unknown in heart failure and preserved ejection fraction (HFpEF). Methods and Results: Baseline IGFBP7 (BL-IGFBP7; n = 302) and 6-month change (Δ; n = 293)
Publikováno v:
Expert review of cardiovascular therapy. 16(7)
INTRODUCTION This review summarizes the current management of heart failure (HF) in patients with reduced ejection fraction and the potential role of heart rate lowering agents in select populations, as recommended in the updated guidelines. Areas co
Publikováno v:
Postgraduate medicine. 130(3)
Levels of natriuretic peptides (NPs), such as B-type NP (BNP) and the N-terminal fragment of its prohormone (NT-proBNP), are well-established biomarkers for patients with heart failure (HF). Although these biomarkers have consistently demonstrated th
Autor:
Biykem Bozkurt, Gregg C. Fonarow, G. Michael Felker, Michael S. Kiernan, Alan S. Maisel, Michael R. Zile, Sheryl L. Chow, Barry H. Greenberg, Peter P. Liu, James L. Januzzi, Inder S. Anand, Clyde W. Yancy, Rudolf A. de Boer, Thomas J. Wang
Publikováno v:
Circulation, 135(22), E1054-E1091. LIPPINCOTT WILLIAMS & WILKINS
Background and Purpose: Natriuretic peptides have led the way as a diagnostic and prognostic tool for the diagnosis and management of heart failure (HF). More recent evidence suggests that natriuretic peptides along with the next generation of biomar
Autor:
Orly Vardeny, Christopher R. Ensor, Robert L. Page, J. Herbert Patterson, J. Thomas Heywood, Robert J. DiDomenico, Barry M. Massie, Sheryl L. Chow, Sherry K. Milfred-LaForest, Wendy Gattis-Stough, JoAnn Lindenfeld, Kathleen Dracup
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 33:529-548
Background Heart failure (HF) care takes place in multiple settings, with a variety of providers, and generally involves patients who have multiple comorbidities. This situation is a “perfect storm” of factors that predispose patients to medicati
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 32:827-837
Despite numerous pharmacologic and nonpharmacologic treatment strategies, heart failure remains a complex, progressive disorder with significant morbidity and mortality. Angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers
Autor:
Tracy Macaulay, Toby C. Trujillo, Shannon W. Finks, Michael P. Moranville, Kelly C. Rogers, Sheryl L. Chow, Anita Airee
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 32:e54-e87
Lifestyle modifications, particularly diet, are a key component to the reduction of cardiovascular events. Diets high in carbohydrates and saturated fat have been shown to negatively affect blood cholesterol, thereby increasing the risk for cardiovas